# Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

> **NCT03734692** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Robert Edwards** · enrollment: 24 (actual)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** Rintatolimod
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03734692
- **Lead sponsor:** Robert Edwards
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-28
- **Primary completion:** 2024-07-01
- **Final completion:** 2027-01-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03734692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03734692, "Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03734692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*